This content is machine translated Heart failure and type 2 diabetes Oral semaglutide and cardiac decompensation in type 2 diabetes The secondary analysis of the SOUL trial from JAMA Internal Medicine 2026 proves for the first time: Oral semaglutide significantly reduces heart failure events in patients with pre-existing HFpEF –...…
